Drug Database
CI

ciclosporin (Gengraf / ciclosporin, AbbVie)

✓ Approved

AbbVie, Inc. · PPIA · 小分子

什么是 ciclosporin?

ciclosporin 是一种小分子,由AbbVie, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Gengraf, ciclosporin, AbbVie
公司AbbVie, Inc.
药物类别小分子
分子靶点PPIA
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

ciclosporin 作用于 1 个分子靶点:

PPIApeptidylprolyl isomerase A (HEL-S-69p, CYPH)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ciclosporin 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Immune system disordersSolid organ transplant rejection✓ Approved

相关研究文献

PubMedVeterinary journal (London, England : 1997)2026-11-08

A blinded, non-inferiority randomised clinical trial comparing the efficacy and safety of low-dose methotrexate and ciclosporin for the control of moderate to severe canine atopic dermatitis.

Rostang Antoine A, Mosca Marion M, Panzuti Pauline P, Pressanti Charline C et al.

Canine atopic dermatitis (cAD) is a chronic, inflammatory skin disease that may require long-term systemic immunomodulatory treatment. Low-dose methotrexate (MTX) is an inexpensive immunomodulator used in human dermatology, but robust veterinary data are lacking. To determine whether weekly subcutaneous low-dose MTX is non-inferior to oral ciclosporin (CsA) in controlling moderate-to-severe cAD. Fifty-five client-owned dogs with non-seasonal moderate-to-severe cAD enrolled at nine dermatology centres in France. Randomised, double-blind, positive-controlled, multicentre non-inferiority trial. Dogs received either subcutaneous MTX (0.15-0.5 mg/kg/week) plus oral placebo, or oral CsA (5 mg/kg/day, then spaced) plus injectable placebo. The primary endpoint was the percentage reduction in the CADESI-04 lesional score on week 28 (non-inferiority margin 20%). Secondary endpoints included the Pruritus Visual Analogue Scale (PVAS) and CADESI-04 scores, assessed 4-weekly, and drug protocol safety assessments. Fifty-five dogs were randomised (MTX n = 28; CsA n = 27). At week 28, mean CADESI-04 reductions were 65.4% (MTX) and 69.5% (CsA), demonstrating non-inferiority. CsA induced faster improvement (weeks 4-12), but efficacy converged by week 20. Gastrointestinal adverse events occurred more frequently with MTX (82%) than with CsA (70%). No consistent haematological, renal or hepatic injury was observed during the study. Two MTX-treated dogs developed severe liver disease during long-term follow-up. Weekly subcutaneous low-dose MTX provided non-inferior control of lesions and pruritus compared with CsA by week 28. Although slower in onset and associated with more gastrointestinal adverse events, MTX may represent an affordable long-term cAD treatment option, with appropriate hepatic monitoring.

PMID 42998873
阅读全文 →
PubMedResearch square2026-11-08

Transcriptomics-based drug repositioning in a neurocysticercosis rat model identifies putative therapeutic candidates reported to mitigate neuroinflammation and neurodegeneration.

Melo Omar O, Huerta Oksana O, Villalobos Karla K, Chile Nancy N et al.

Neurocysticercosis (NCC) is a major cause of epilepsy and neurological symptoms in low- and middle-income countries. Although antiparasitic treatment targets the parasite, it often fails to fully resolve symptoms and can exacerbate brain tissue damage. Using a rat model of NCC and transcriptomic profiling, we assessed the effects of infection and treatment on brain gene expression to uncover disease molecular pathways and identify putative therapeutic candidates through in silico drug repurposing. We analyzed transcriptomic profiles at two stages of infection (4- and 6-month post-infection (MPI)), and after treatment at 6 MPI (6 MPI +T). At 6 MPI, fewer immune-related genes and pathways were enriched compared to 4 MPI, likely due to MAPK pathway repression, but immune activation increased significantly after treatment, possibly due to cyst degeneration. Drug repositioning identified 30 candidate drugs. Among these, vorinostat, ciclosporin, papaverine, valproic acid, and chlorpromazine have been reported to mitigate neuroinflammation and neurodegeneration. Taken together, these results provide a molecular rationale for drug repositioning in neurocysticercosis; however, further experimental validation in larger cohorts is required to confirm the therapeutic potential of the identified candidates.

PMID 42996327
阅读全文 →
PubMedTherapie2026-11-05

Systemic treatments of psoriasis and atopic dermatitis in adults and children: From pharmacological targets to meta-analyses.

Marcombes Clarisse C, Ouakrat Raphaël R, Sbidian Emilie E, Le Cleach Laurence L

Psoriasis and atopic dermatitis (AD) are chronic immune-mediated inflammatory skin diseases that can substantially impair quality of life. Over the past two decades, their systemic treatment has undergone major changes, driven by advances in the understanding of their pathophysiology and the identification of specific therapeutic targets. To provide a narrative overview of the systemic treatments currently available or under development for psoriasis and AD in adults and children, describing their mechanisms of action, therapeutic positioning, efficacy, and main safety considerations. Systemic treatment has progressively evolved from broad immunosuppressive and immunomodulatory agents, such as methotrexate and ciclosporin, toward increasingly selective targeted therapies. In psoriasis, this evolution has led to biologics targeting TNF-α, IL-12/23, IL-17, IL-23 and IL-36, as well as oral targeted therapies including PDE4 and TYK2 inhibitors. In AD, therapies targeting IL-4/IL-13, IL-13 and IL-31 have expanded treatment options, while oral JAK inhibitors provide rapid and effective control of both skin inflammation and pruritus. These advances have progressively extended to pediatric populations, although conventional systemic treatments remain frequently used in children. The growing number of available therapies has also increased the need for comparative evidence. Network meta-analyses suggest particularly high efficacy of IL-17 and IL-23 inhibitors in psoriasis, while JAK inhibitors and IL-4/IL-13-targeted therapies are among the most effective options for AD. However, indirect comparisons should be interpreted cautiously because of heterogeneity between trials, limited long-term safety data, and the paucity of head-to-head studies. The systemic treatment landscape of psoriasis and AD has shifted from non-specific immunosuppression toward targeted and increasingly personalized approaches. Future research should address long-term treatment strategies, rare adverse events, patient-reported outcomes, and clinical and biological factors that may guide individualized treatment selection.

PMID 42988663
阅读全文 →
PubMedHematology (Amsterdam, Netherlands)2026-10-29

Daratumumab in immune-mediated thrombotic thrombocytopenic purpura: emerging evidence for plasma cell-targeted therapy.

Mohammed Saleh Mostafa F MF, Alzaidy Nourah N, Nassani Momen M, Abdrabou Ahmed Kotb AK et al.

Immune mediated thrombotic thrombocytopenic purpura is a life threatening autoimmune thrombotic microangiopathy caused by severe ADAMTS13 deficiency due to inhibitory autoantibodies. Despite plasma exchange, corticosteroids, rituximab, and caplacizumab, some patients develop refractory disease or persistent and relapsing ADAMTS13 deficiency. To summarize the mechanistic rationale, clinical efficacy, safety, and potential therapeutic role of daratumumab in refractory or frequently relapsing immune mediated thrombotic thrombocytopenic purpura. A structured narrative review was conducted across five major bibliographic databases, PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and Web of Science, from database inception through September 13, 2026. Searches of major hematology journal databases were also performed. Case reports, case series, registry analyses, multicenter cohort studies, and conference abstracts describing the use of daratumumab in acquired immune-mediated thrombotic thrombocytopenic purpura (iTTP) were included. Clinical setting, treatment regimen, ADAMTS13 response, time to response, relapse, and adverse events were extracted and qualitatively synthesized. Because reports differ in populations, endpoints, concomitant therapy, and possible patient overlap, findings were synthesized qualitatively without a pooled response estimate. Six key clinical reports involving more than 40 patients were identified. Most patients had received multiple previous therapies, including plasma exchange, corticosteroids, rituximab, and caplacizumab. Daratumumab was administered intravenously at 16 mg/kg or subcutaneously at 1,800 mg, usually weekly for two to six doses. Across the available reports, ADAMTS13 recovery was observed in a substantial proportion of treated patients, although reported response rates varied according to the populations studied and the thresholds used to define response. Recovery commonly occurred within several weeks. Multicenter reports also described sustained remission in a proportion of responders, although biochemical relapse remained frequent during follow-up. Adverse events were generally manageable, with predominantly mild infusion reactions and infrequent serious infections. Other individualized treatment strategies described after rituximab failure or intolerance include bortezomib, optimized or alternative anti-CD20 therapy, ciclosporin, azathioprine, and mycophenolate. Daratumumab is a promising plasma cell directed therapy for rituximab refractory or frequently relapsing immune mediated thrombotic thrombocytopenic purpura. Prospective studies are required to define its role within treatment algorithms.

PMID 42954430
阅读全文 →
PubMedFrontiers in allergy2026-10-25

From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticaria.

Elkhalifa Shuayb S, Abuzakouk Mohamed M

Chronic spontaneous urticaria is a common, mast cell driven condition that presents with wheals, angioedema, or both, and a substantial proportion of patients remain inadequately controlled despite guideline-directed antihistamine therapy. The 2026 guideline has expanded the advanced-treatment options to include omalizumab, dupilumab and remibrutinib, while ciclosporin remains an alternative later-line immunosuppressive option, yet it is organised around treatment response rather than prognosis, so patients with difficult-to-control disease are often recognised only after months of sequential escalation. This narrative review examines the scoring systems and biomarkers available in urticaria and angioedema and considers whether they can support early risk stratification and help identify patients at increased risk of difficult-to-control disease. The validated instruments in routine use, namely the Urticaria Activity Score, the Urticaria Control Test, the Chronic Urticaria Quality of Life Questionnaire, and their angioedema counterparts, measure current disease activity, control, and quality of life rather than long term outcome. A separate body of work has described biomarkers associated with the autoimmune type IIb endotype and with response to omalizumab, including low total IgE, a high ratio of IgG anti-thyroid peroxidase to total IgE, basopenia, and raised inflammatory markers, although most of this evidence is associative rather than prospectively predictive. The distinction between markers of current burden, markers of prognosis, and markers of treatment response is emphasised. Composite models integrating clinical characteristics, patient-reported outcomes, and biomarkers represent a promising approach toward precision management of CSU, although no validated prognostic tool is currently available for routine clinical use.

PMID 42922821
阅读全文 →
PubMedGlobal & regional health technology assessment2026-10-15

Determining value and the contribution of ciclosporin-based therapies in dry eye disease: a European expert MCDA pilot study.

Ahmad Sajjad S, Figueiredo Francisco F, Labetoulle Marc M, Messmer Elisabeth M EM et al.

Dry eye disease (DED) is a multifactorial, immune-mediated inflammatory condition affecting the ocular surface and lacrimal glands. Multiple ciclosporin-based therapies with different formulations are currently available in Europe, although clear guidance on their optimal use remains limited. The aim of this study was to determine the main unmet needs and the current management landscape of ciclosporin-based therapies, from the perspective of clinical experts using multi-criteria decision analysis (MCDA). A systematic literature review was conducted to gather evidence for each of the MCDA framework criteria. An international expert panel of seven clinical specialists in DED from four European countries independently weighted the criteria and scored the non-comparative criteria in the evidence matrix. Results were presented and discussed in a group online session. DED is a highly prevalent, chronic inflammatory disease associated with significant visual and functional burden. Its management is not uniform and often involves a stepwise approach. Recent ciclosporin-based treatment alternatives address some unmet needs; however, others-such as the need for greater standardization of diagnostic tools and improved objective markers of inflammation-remain to be addressed. Highest importance was assigned to Efficacy/effectiveness (4.7 ± 0.5), Quality of evidence (4.7 ± 0.5), and Safety/tolerability (4.6 ± 0.5) criteria, highlighting the relevance of treatment-related outcomes in clinical decision-making. The expert opinion, based on MCDA, enabled the identification of key value drivers and unmet needs in the current management of DED based on ciclosporin-based therapies. These early insights may contribute to promoting future work to support informed, evidence-based decision-making.

PMID 42876972
阅读全文 →

注册免费账户还可查看另外 2324 篇文献

免费注册查看全部文献 →

了解更多ciclosporin